SUMMARY Hydralazine reduces pulmonary vascular resistance in patients with primary and secondary pulmonary hypertension, but the effects on right ventricular function of a change in resistance without a reduction in pulmonary arterial pressure are not known. We evaluated the hemodynamic effects of hydralazine, 50 mg, administered orally every 6 hours for 48 hours in 14'patients with right ventricular failure and pulmonary hypertension resulting from various causes. Hydralazine reduced mean right ventricular end-diastolic pressure from 17.4 + 5.6 to 11.6 5.3 mm Hg (p < 0.0001) 'and increased cardiac output and stroke volume by more than 40%. In nine patients who had no change in mean pulmonary arterial pressure after hydralazine, total pulmonary resistance decreased from 15.9 6.0 to 10.6 ± 4.3 (p < 0.001) and cardiac index increased from 2.07 ± 0.51 to 2.97 ± 0.91 (p <-0.005). There was a close correlation between the reductions in total pulmonary resistance and right ventricular end-diastolic pressure (r = 0.73)). These data suggest that hydralazine can increase cardiac output and reduce right ventricular end-diastolic pressure even when pulmonary arterial pressure remains unchanged.
PULMONARY HYPERTENSION accompanies various cardiopulmonary disorders, including chronic obstructive and restrictive lung diseases, pulmonary thromboembolism, primary pulmonary hypertension and patent or surgically corrected intracardiac septal defects. The sustained elevation in right ventricular afterload seen in these conditions increases right ventricular work and ultimately leads to right ventricular failure. Systemic vasodilators are useful in treating patients with congestive heart failure' because they reduce left ventricular afterload.'' We' recently demonstrated that in addition to its systemic effects, hydralazine reduces pulmonary arteriolar resistance at rest and' during exercise'in patients with either primary pulmonary hypertension" or pulmonary'hypertension secondary to chronic hypoxic lung disease. 6 In patients with pulmonary hypertension who respond to the administration of a vasodilator by reducing pulmonary vascular resistance without changing pulmonary arterial pressure, right ventricular afterload may not improve.7 Our preliminary observations seemed to confirm this concept, as five of our six patients with right ventricular failure who manifested a reduction in right ventricular end-diastolic pressure (RVEDP) after the administration of hydralazine had significant reductions in mean pulmonary arterial pressure as well.6
Several of our patients who responded to hydralazine by reducing pulmonary vascular resistance but not pulmonary arterial pressure have had symptomatic improvement and a reduction in the signs of right ventricular failure. Therefore, perhaps the functional state of the right ventricle could be improved by a vasodilator without changing pulmonary arterial pressure. This response may be similar to the effects of hydralazine in normotensive patients with left ventricular failure: Cardiac output increases and left ventricular filling pressure may decrease despite little or no change-in systemic blood pressure. 2 8, 9 To further clarify the effects of'vasodilators on right ventricular function, we evaluated the effects of hydralazine in 14 patients with pulmonary hypertension and right ventricular failure.
Methods
Fourteen patients who had isolated right ventricular failure were evaluated at Duke University Medical Center between November 1977 and June 1980. Causes of pulmonary hypertension included surgically corrected atrial septal 'and ventricular septal defects in two patients each, unrepaired atrial septal defect in one patient, primary pulmonary hypertension in three patients, chronic or recurrent pulmonary thromboembolism in two, chronic obstructive airways disease in two, and scleroderma with pulmonary fibrosis in two. Right ventricular failure was defined as the presence of hepatomegaly, ascites or edema in patients with an RVEDP greater.than 10 mm Hg. All patients were clinically stable at the start of the study and were maintained on their chronic medical regimen during the study. Medications included cardiac glycosides, diuretics, bronchodilators, glucocorticoids and supplemental oxygen. No patient had clinical or hemodynamic evidence of left ventricular failure, known coronary artery disease or mitral or 'aortic valve disease. Informed consent was obtained from each patient before the study.
The right heart was catheterized from an antecubital or internal jugular vein using a Swan-Giainz catheter. The reference point for the pressure trans-VOL 65, No 7, JUNE 1982 Abbreviations: SAPm = mean systemic arterial pressure; PAPm = mean pulmonary arterial pressure; PA satn = pulmonary artery oxygen saturation; RA = mean right atrial pressure; RVEDP = right ventricular end-diastolic pressure; PCW = pulmonary capillary wedge pressure; CI = cardiac index; HR = heart rate; TPR = total pulmonary resistance; PAR = pulmonary arteriolar resistance; VSD = ventricular septal defect; ASD = atrial septal defect; COPD = chronic obstructive pulmonary disease. ducers was at the midchest level with the patient supine. A plastic arterial cannula was inserted into either brachial artery for blood sampling and systemic pressure monitoring. Resting supine pressures were measured from the right atrium, right ventricle, pulmonary artery, pulmonary capillary wedge and brachial artery. Mean pressures were obtained by electronic integration. Cardiac output was determined by the Fick method in duplicate and heart rate was monitored using a continuous lead II ECG.
After the control measurements were performed, the catheters were removed and the patients were given a test dose of 25 mg of hydralazine by mouth. When this dose was tolerated, 50 mg of hydralazine were administered orally every 6 hours for the subsequent 48 hours. Blood' pressure and heart rate in the supine and standing positions were'monitored on the ward. After eight'doses of the drug, the patients returned to the cardiovascular laboratory and they underwent the identical procedure. The' final dose of CIRCULATION hydralazine was administered within 1 hour of the repeat catheterization. The data are presented as the mean + SD. Statistical analysis of the data was performed using the two-tailed t test for paired data.
Results
The effects of hydralazine on RVEDP in each of the 14 patients are shown in figure 1 . The mean RVEDP decreased from 17.4 ± 5.6 to 11.6 ± 5.3 mm Hg (p < 0.0001). Table 1 summarizes the control and postdrug hemodynamic data. The patients were divided into two groups based on the response of pulmonary arterial pressure to hydralazine. The five patients in group 1 had significant reductions in mean pulmonary arterial pressure, while the nine patients in group 2 did not. Cardiac index increased more in group 2 than in group 1 (43% vs 25%) and total pulmonary resistance (TPR) decreased slightly more in group 2 than in group 1 (33% vs 27%) after hydralazine. Baseline RVEDP levels were similar and were comparably reduced after hydralazine. Heart rate increased slightly in both groups. Systemic arterial pressure decreased significantly in group 1 but not in group 2. Oxygen consumption was unchanged after hydralazine (control mean 266 ± 31 ml/min; posthydralazine 273 ± 26 ml/min).
To correlate the reduction in RVEDP with changes in other hemodynamic variables, a linear regression analysis was performed. In group 1, changes in RVEDP after hydralazine correlated with changes in mean pulmonary arterial pressure and TPR ( fig. 2) , while the best correlations with RVEDP in group 2 were seen with stroke volume index and TPR ( fig. 3) . In the seven patients in group 2 in whom pulmonary artery wedge pressures were measured before and after hydralazine, the reduction in RVEDP correlated 25- with clinical evidence of right ventricular failure compared with that in normal subjects. Diuretics have also been advocated in the treatment of right-heart failure because they decrease edema; however, in doing so, they may further decrease preload and reduce cardiac output. In addition, the hypokalemia that commonly occurs with diuretic use potentiates the risk of digitalis toxicity. Neither of these modalities significantly affect right ventricular afterload, which is the cause of right ventricular failure in pulmonary hypertensive states. Our data show that hydralazine has a beneficial hemodynamic effect in patients with right ventricular failure, even when pulmonary arterial pressure is unchanged. The reduction in RVEDP concomitant with an increase in stroke volume implies improved systolic emptying of the right ventricle, and the correlation with the reduction in TPR suggests that this improvement is related to a reduction in right ventricular afterload.
Changes in the other determinants of cardiac output well with the reduction in calculated pulmonary arteriolar resistance (r = 0.80). Discussion The treatment of right ventricular failure secondary to pulmonary heart disease is controversial. Cardiac glycosides reduce right-sided filling pressures and increase cardiac output when they are given acutely to patients with right-heart failure.0' 11 Berglund et al., '2 however, reported that digitalis had little or no effect on hemodynamics of patients with right ventricular failure. Digitalis enhances the contractile state of the right ventricle,13 but Stein et al.14 showed that right ventricular maximal dP/dt was augmented in patients do not explain this beneficial effect of hydralazine. The small increase in heart rate does not account for the increase in cardiac output, for stroke volume increased by 40%. It is also unlikely that cardiac output increased as a result of an improvement in left ventricular function, as left ventricular filling pressures were normal before and after therapy. Although it has been suggested that hydralazine increases myocardial contractility,"' conventional doses do not have this effect."' Further, if cardiac output increased solely as a result of an inotropic effect, pulmonary arterial pressure would have increased. Because hydralazine has no significant effect on venous tone,"7 the reductions in RVEDP and right atrial pressure cannot be attributed to a decreased preload resulting from venous pooling.
The effects of hydralazine on left ventricular filling pressure are inconsistent;2' 8, 9, 18, 1 some investigators report significant reductions and others note no change. There are several possible explanations for the reduction in RVEDP after hydralazine therapy. The improved renal blood flow resulting from the increased cardiac output could cause a diuresis and decrease the intravascular volume. In fact, all eight patients weighed before and after hydralazine had a weight loss of 0.4-1.7 kg, but there was no clear correlation between the reductions in RVEDP and weight. By reducing right ventricular afterload, hydralazine might have decreased tricuspid or pulmonic regurgitation and redistributed right ventricular systolic volume so that regurgitant volume decreased.
In conclusion, oral hydralazine increased cardiac output and reduced RVEDP even in patients who had no change in mean pulmonary arterial pressure. The reduction in RVEDP correlated with the reduction in pulmonary vascular resistance. These data suggest that hydralazine reduces right ventricular afterload in right-heart failure, and that a reduction in pulmonary vascular resistance is a clinical reflection on this effect.
